Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)

This study is currently recruiting participants.
Verified December 2013 by GITR, Inc.
Sponsor:
Collaborator:
Cancer Research Institute, New York City
Information provided by (Responsible Party):
GITR, Inc.
ClinicalTrials.gov Identifier:
NCT01239134
First received: November 9, 2010
Last updated: December 17, 2013
Last verified: December 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2014
  Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)